Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Published version of a preprint

Abstract

MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. RG7112 is a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies. RG7112 binds MDM2 with high affinity (KD ∼ 11 nmol/L), blocking its interactions with p53 in vitro. A crystal structure of the RG7112–MDM2 complex revealed that the small molecule binds in the p53 pocket of MDM2, mimicking the interactions of critical p53 amino acid residues. Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis. RG7112 showed potent antitumor activity against a panel of solid tumor cell lines. However, its apoptotic activity varied widely with the best response observed in osteosarcoma cells with MDM2 gene amplification. Interestingly, inhibition of caspase activity did not change the kinetics of p53-induced cell death. Oral administration of RG7112 to human xenograft-bearing mice at nontoxic concentrations caused dose-dependent changes in proliferation/apoptosis biomarkers as well as tumor inhibition and regression. Notably, RG7112 was highly synergistic with androgen deprivation in LNCaP xenograft tumors. Our findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53. Cancer Res; 73(8); 2587–97. ©2013 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-2807

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 26 references

Cited by

See all 326

Metadata

Authors
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., Linn, M., Podlaski, F., Wovkulich, P., Vu, B., & Vassilev, L. T.
Affiliations
Authors' Affiliation: Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey
Venue
Cancer Research
Published
2013-04-15
Volume
73
Issue
8
Pages
2587-2597
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2098748257
Cited by
283
References
26
Citations by year
2026: 7 · 2025: 12 · 2024: 10 · 2023: 30 · 2022: 24 · 2021: 19 · 2020: 19 · 2019: 19 · 2018: 16 · 2017: 19 · 2016: 30 · 2015: 37 · 2014: 29 · 2013: 12
FWCI
20.69
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
RG7112, nutlin, MDM2 inhibitors, p53 activation, p53 stabilization, cell cycle arrest, apoptosis, solid tumors, osteosarcoma, MDM2 amplification, LNCaP xenografts, androgen deprivation therapy, caspase inhibition, oral antitumor activity
MeSH terms
Animals, Antineoplastic Agents, Disease Models, Animal, Female, Humans, Neoplasms, Protein Binding, Signal Transduction, Tumor Suppressor Protein p53, Apoptosis, Caspases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Imidazolines, Mice, Proto-Oncogene Proteins c-mdm2, Protein Stability, Cell Cycle Checkpoints, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2807
The paper
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., Linn, M., Podlaski, F., Wovkulich, P., Vu, B., & Vassilev, L. T. (2013). MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2807

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.